{"groups":[{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 8 milligram per square meter (mg/m\\^2), capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of disease progression (PD), clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"FG000","title":"Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2"},{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"FG001","title":"Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2"},{"description":"Participants with recurrent or refractory ewing sarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"FG002","title":"Phase 2: Cohort 1, Ewing Sarcoma"},{"description":"Participants with recurrent or refractory rhabdomyosarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"FG003","title":"Phase 2: Cohort 2, Rhabdomyosarcoma"},{"description":"Participants with recurrent or refractory high grade glioma (HGG) received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"FG004","title":"Phase 2: Cohort 3, HGG"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"7"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"Sponsor's decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"20"},{"groupId":"FG004","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"18"},{"groupId":"FG004","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 86 participants were screened, out of which 64 were enrolled and 9 participants completed the study.","recruitmentDetails":"Participants took part in the study at 24 investigative sites in the United States and Canada from 16 November 2017 to 30 September 2022."}